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uterine sarcoma
uterusTable 1
Useful key factors to distinguish benign and mal
neoplasms.
Identify benign ESN
(1) Adequate sampling of the border/surround
emyometrial interface)
(2) The projections into the adjacent myometrium <
mass
(3) The projections into the adjacent myometrium
(4) Absence of vascular invasion
Identify HG-ESS
(1) In a tumor with marked mitotic activity (>20e
ﬁelds)
(2) Loss of hormone receptors
(3) Additional sampling to exclude the possibility
myxoid appearance
(4) Negative for smooth muscle markers
(5) Diffusely positive for c-kit but negative for DOG
(6) Diffusely positive for cyclin D1 but negative for E
cytokeratin
Identify UUS
(1) Lacking smooth muscle or endometrial stromal
(2) Destructive myomatrial inﬁltration, a fascicu
pattern, highly pleomorphic cells (nondescript c
(3) Positive CD10 immunoactivity
(4) Lacking the deﬁning genetic rearrangement
genomic gains and losses without speciﬁc trans
CD10¼ cluster of differentiation 10; DOG1¼Discove
mal tumors protein 1; EMA¼ Epithelial Membrane
stromal nodule; HG-ESS¼ high-grade endometrial str
undifferentiated sarcoma.based on the identiﬁcation of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene fusion, typically present with
advanced stage diseases and frequently have recurrences, usually within a few years after initial surgery.
UUS is, a high-grade sarcoma, extremely rare, lacking a speciﬁc line of differentiation, which is a diag-
nosis of exclusion (the wastebasket category, which fails to fulﬁll the morphological and immunohis-
tochemical criteria of translocation-positive ESS). Surgery is the main strategy in the management of
uterine sarcoma. Due to rarity, complex biological characteristics, and unknown etiology and risk factors
of uterine sarcomas, the role of adjuvant therapy is not clear. Only LG-ESS might respond to progestins or
aromatase inhibitors.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Endometrial stromal tumors (EST) account for less than 1% of all
uterine tumors [1], which can be divided into four main categories,
currently recognized by the World Health Organization, including
endometrial stromal nodule (ESN); endometrial stromal sarcoma
(ESS), low-grade (LG-ESS); endometrial stromal sarcoma, high-
grade (HG-ESS); and uterine undifferentiated sarcoma (UUS) [2].
Endometrial stromal tumors, especially LG-ESS, represent the sec-
ond most common category of mesenchymal uterine tumors (sec-
ond to uterine leiomyosarcoma [uLMS]) [3]. A stage system, similar
to the uLMS, has been introduced in the previous issue of the
Taiwanese Journal of Obstetrics and Gynecology [3]. In brief, a tu-
mor limited to the uterus is Federation International Gynecology
and Obstetrics (FIGO) I [<5 cm in diameter (IA) and 5 cm (IB)]; a
tumor limited to pelvic cavity but extended beyond the uterus is II
[an adnexal involvement (IIA) and other pelvic cavity invasion
(IIB)]; tumor outside the pelvic cavity is III [positive retroperitoneal
lymph node metastases (IIIC)]; tumor invaded to bladder and
rectum is IVA, and distant metastases is IVB [3].
To distinguish benign and malignant is based on the type of
tumor margin, although it is sometimes not easy to deﬁne the
category. The following key points may help to deﬁne the benign
andmalignant ESS (Table 1). In general, awell-circumscribed tumorignant endometrial stromal
ing myometrium (tumor
3mm from themain tumor
<3 in number
30 mitoses/10 high-power
of HG-ESS for ﬁbrous or
1
MA and/or broad spectrum
differentiation
lar or patternless growth
ells)
(complex karyotypes and
locations)
red On Gastrointestinal stro-
Antigen; ESN¼ endometrial
omal sarcoma; UUS¼ uterineis diagnosed as benign stromal nodules, whereas those exhibiting
myometrial invasion and lymphovascular space (LVS) invasion are
malignant [3]. Occasionally, benign ESN might have focal irregu-
larity of the border and form ﬁnger-like or nodular projections.
However, these unusual presentations should not extend >3 mm
from the main tumor mass. As shown above, total absence of LVS
invasion of these tumors (ESN) is considered a benign tumor [2].
ESN
ESN is benign. The tumor is usually presented with abnormal
vaginal bleeding or as an incidental ﬁnding in a hysterectomy
specimen performed for other reasons [4]. Grossly, ESN is a well-
circumscribed tumor with a ﬂeshy and soft yellow to tan cut sur-
face and can be found as an intramural mass or as a polypoid tumor
protruding into the endometrial cavity [4]. Microscopically, ESN is
expansible in nature without myometrial invasion and absence of
LVS invasion. An immunohistochemical proﬁle did not help to
distinguish ESN and LG-ESS, suggesting that conventional
morphological and histological features are important for the
diagnosis of ESN [4].
LG-ESS
Overview
LG-ESS affects women primarily in the perimenopausal age
group and more than half of patients were diagnosed pre-
menopausally [1,2]. The most commonly presented symptoms or
signs were abnormal uterine bleeding, pelvic pain, and dysmen-
orrhea [1,2]. Nearly one-third of patients present with symptoms or
signs related to extrauterine spread and one-fourth of patients are
asymptomatic [1,2]. The most frequent site of extrauterine pelvic
extension is the ovary [1]. Extrauterine pelvic extension of LG-ESS is
also frequently associated with endometriosis [4]. LG-ESS might
manifest as an endometrial polyp, such that endometrial biopsy is
more likely to be diagnostic [5]. Obesity, diabetes, younger age at
menarche, and tamoxifen intake are associated with increased risk
of LG-ESS [5].
Pathology
Grossly, LG-ESS may be submucosal or intramural, usually with
ill-deﬁned borders and wormlike permeation within the myome-
trium and parametrial tissue [6]. LG-ESS can form multiple poorly
deﬁned, frequently coalescent, ﬂeshly tan to yellow, soft nodules
within the endometrium and myometrium. LG-ESS appears paler,
ﬁrmer and gray if the tumor underwent smooth muscle differen-
tiation. Microscopically, LG-ESS shows extensive permeation of the
myometrium as irregular islands with frequent LVS invasion [5],
and the “tongue-like” patterns of myometrial and LVS invasion are
Table 2
Common genetic alterations in ESS.
LG-ESS
t(7;17)(p15;q21)/ the fusion of JAZF1 and SUZ12(JJAZ1) genes at 7p15 and
17q21, respectively
t(6;7)(p21;p15)/ the JAZF1ePHF1 fusion gene at 7p15 and 6p21, respectively
t(6;10)(p21;p11)/ the PHF1eEPC1 fusion gene at 6p21 and 10p11,
respectively
t(1;6)(p34;p21)/ the PHF1eMEAF6 fusion gene at 6p21 and 1p34,
respectively
t(X;22)(p11;q13)/ the ZC3H7BeBCOR fusion gene at Xp11 and 22q13,
respectively
t(X ;17) (p11.2;q21.33)/ the MBTD1-CXorf67 fusion gene at Xp11.2 and
17q21.33, respectively
HG-ESS
t(10;17)(q22;p13)/ the YWHAE-FAM22 (NUTM2AB) fusion gene at 10q22 and
17 p13, respectively
ESS¼ endometrial stromal sarcoma; HG-ESS¼ high-grade endometrial stromal
sarcoma; LG-ESS¼ low-grade endometrial stromal sarcoma.
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ESN [6]. LG-ESS cells have bland nuclear features with monotonous
oval to spindle nuclei that resemble proliferative phase endome-
trial stroma, with low mitotic activity (<5/10 high power ﬁelds),
and without necrosis [2].
Immunohistochemically, LG-ESS is a typical positive cluster of
differentiation 10 (CD10), vimentin, actins, WT-1, IFITM1, estrogen
receptor [(ER), only alpha isoform], androgen receptor, and pro-
gesterone receptor (PR) [2]. In fact, it is occasionally hard tomake an
accurate diagnosis of LG-ESS. The differential diagnosis should
include gland-poor adenomyosis, cellular leiomyoma, intravascular
leiomyomatosis, uLMS with extensive intravascular component,
HG-ESS, uterine tumor resembling ovarian sex-cord tumor, peri-
vascular epithelioid cell tumor and gastrointestinal stromal tumor
[6]. A recent article was conducted to evaluate an immunohisto-
chemical panel differentiating ESS from uLMS and leiomyoma and
found that the combination of ER(þ)/PR(þ)/CD10(þ)/GEM()/h-
caldesmon()/transgelin() could predict ESS versus uLMSwith an
area under the curve predictive value of 0.872 (95% conﬁdence in-
terval [CI] 0.784e0.961, p< 0.0001) and the combination of ER(þ)/
PR(þ)/CD10(þ)/h-caldesmon()/transgelin() could predict LG-
ESS from low-grade uLMS with an area under the curve predictive
value of 0.914 (95% CI 0.832e0.995, p< 0.0001) [6], suggesting that
it is important to use a panel of immune-stains that includes CD10
and at least two smooth muscle markers (for example, desmin, h-
caldesmon, smooth muscle heavy chain myosin, HDAC8) as there is
no single marker that is speciﬁc for ESS [5,7].
The majority of LG-ESS harbors chromosomal rearrangement
[2,6]. The most common genetic abnormality is t(7;17)(p15;q21),
resulting in the fusion of JAZF1 (juxtaposed with another zinc ﬁnger
gene 1) and SUZ12(JJAZ1) genes (polycomb repressive Complex 2
subunit) at 7p15 and 17q21, respectively [2,6]. The reported fre-
quency of JAZF1-JJAZ1 fusion is nearly 50% in LG-ESS cases [6]. The
second most frequent abnormality is t(6;7)(p21;p15), resulting in
the fusion of JAZF1 and PHF1 genes (Cys4-His-Cys3 motif in the
plant homeodomain (PHD) ﬁnger Protein 1) at 7p15 and 6p21,
respectively [2,6]. Much less common genetic abnormality,
including that the PHF1 gene at 6p21 could also fuse with EPC1
(enhancer of polycomb 1) at 10p11 and MEAF6 at 1p34 [2,6], or
ZC3H7-BCOR and MBTD1-CXorf67 have been also reported [8,9].
PHF1 genetic rearrangement might result in sex cord-like differ-
entiation in LG-ESS [2], which might make a pitfall to distinguish
LG-ESS from a uterine tumor resembling an ovarian sex-cord tu-
mor. Table 2 shows the summary of common genetic abnormalities
of LG-ESS.
Image
The prediction of malignancy is of utmost importance; however,
uterine sarcoma could be predicted by clinical characteristics
[10e12]. In addition, data on the prediction of uterine sarcoma by
ultrasound examination are scare and only limited information on
their ultrasound features has been reported to date. Based on
investigating 10 patients with LG-ESS, ultrasound ﬁndings of LG-
ESS are variable with regard to the location, margin, and conﬁgu-
ration of the lesion [13]. Among these ultrasound ﬁndings, multi-
septated cystic areas and multiple small areas of cystic
degeneration are most common [13]. Magnetic resonance image
may have a developing role in the assessment of uterine masses.
LG-ESS may appear as a polypoid endometrial mass, with low
signal on T1-weighted images and heterogeneously increased high
T2 signal [11]. These malignant tumors (LG-ESS, HG-ESS, and UUS)
typically havemyometrial invasion, either sharply demarcated or in
a more diffuse and destructive manner (especially for UUS) [11].
ESS has a tendency for lymphovascular invasion, showing worm-like extension bands of low signal intensity within areas of myo-
metrial involvement on T2-weighted image, similar to a bag of
worms, corresponding to preserved bundles of myometrium [11].
Contrast-enhancement is moderate and often heterogeneous [11].
However, these features are neither speciﬁc nor sensitive for the
diagnosis of malignant or benign lesions. Sumi et al [14] used
contrast ratio of signal intensity in T2-weighted images for the
areas of lowest, highest, and main signal intensity of each tumor as
well as contrast-enhanced ratio for the main solid part of each
tumor in contrast-enhanced T1-weighted images to perform
quantitative assessment for distinguishing benign and malignant
uterine tumors, and found that the contrast-enhanced ratio for ESS
showed the most homogeneous enhancement; however, the
reproducibility needs further conﬁrmation.
Treatment
LG-ESS is an indolent tumor with a favorable prognosis, but
characterized by late recurrences even in patients with Stage I
disease, suggesting the requirement of a long-term follow-up
[1,15,16]. In addition, in the literature review, recurrent LG-ESS can
occur 10e20 years after the initial diagnosis [17]. Stage is the most
signiﬁcant prognostic factor, and 5-year overall survival (OS) rate
for Stage I patients is more than 90%, but decreased to 50% for Stage
III and IV [1,16]. The most common sites for recurrence are pelvis
and abdomen [1].
Surgery is the most important procedure in the management of
patients with LG-ESS. Hysterectomy and bilateral salpingo-
oophorectomy (BSO) is a preferred procedure. LG-ESS is often sen-
sitive to hormones, therefore, BSO may play an important role to
cease the hormone production. The beneﬁts of BSO for womenwith
LG-ESS can be further supported indirectly by the following obser-
vation: (1) withdrawing estrogen replacement therapy and
tamoxifen can result in stable disease ofwomenwith LG-ESS [17,18];
(2) aromatase inhibitors (AIs) might have partial responses and
even achieve complete responses in these women with LG-ESS
[18e20]; high-dose progestins and antiprogestin agents were the
key component in themanagement of these LG-ESS patients [17,20].
Therefore, hormone replacement therapy for menopausal syn-
drome is contraindicated, and progestins (megestrol and medrox-
yprogesterone acetate) or AIs are the therapeutic choice in the
management of women with LG-ESS, especially acting as post-
operative adjuvant therapy for residual or recurrent diseases [20].
A Phase II study showed that single-agent mifepristone (RU-
486) in the management of LG-ESS could result in a stable disease
rate of 50% [17]. There are two categories of AIs available in the
market, based on their chemical structure [21]. Type I AIs are
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bonds, while Type II AIs are nonsteroidal inhibitors that bind
reversibly and covalently with aromatase [21]. Exemestane is a
Type I AI whereas letrozole and anastrozole are Type II AIs [22]. One
retrospective study evaluated the effect of AIs in the management
of 16 ESS patients, and found an overall response rate of 67% (60%
partial response rate, 7% complete response rate) and a 20% stable
disease rate in these patients [23].
Not all patients can receive completely destructive surgery, such
as hysterectomy and BSO, even though the procedure is highly
recommended as the therapeutic choice in the management of
womenwith LG-ESS. These women might be young, and might not
have completed their family. Therefore, conservative treatment to
maintain the reproductive function is the aim of these women
[24e27]. The question is raiseddis it possible to preserve the
reproductive function for these women with LG-ESS? In fact, a
similar concept has been well-accepted in the management of
endometrial cancer [28e30], which fulﬁlls the following criteria:
(1) younger than 40 years; (2) having a strong desire to preserve
fertility; (3) having a need to give birth; (4) having the ability to
give birth; (5) having to get pregnant immediately after tumor
regression; (6) pathologically-conﬁrmed LG-ESS; (7) limited to
2009 FIGO IA stage or highly selected IB; (8) having a good
compliance; (9) no contraindication for high-dose progestin or
other hormone therapies.
Due to similar response to progestin treatment in both Type I-
Grade I endometrial endometrioid carcinoma and LG-ESS, it is
reasonable to maintain part or total reproductive function [30],
such as ovary and/or uterus for these relatively indolent diseases
[31]. Two small series reported in China evaluated 5 and 19 patients
with LG-ESS, who received conservative surgeries of local resection
of the tumors with uterine reconstruction [26] or myomectomy
[32], respectively. The patients then received megestrol acetate
(160e320 mg/day) or gonadotropin-releasing hormone agonist for
5e6 months [26], or no treatment (due to pathological misdiag-
nosis) [32]. During the follow-up, three uterine reconstruction
patients and ﬁve myomectomy patients ﬁnally had a successful
birth [26,32]; suggesting that fertility-sparing treatment might be
suitable in highly selected younger women with LG-ESS, especially
for thosewhose lesion showed a clear border and could be removed
by complete en bloc resection. Of course, adjuvant endocrine ther-
apy, especially the use of high-dose progestins, is highly recom-
mended for 6 months after the operation. Although the above-
mentioned report is promising [26], one report in Japan showed
the fatal case of ESS 10 years after fertility-sparing management
[27]. In addition, all 19 patients who underwent myomectomy for
LG-ESS did have recurrence [32], suggesting that hysterectomy and
BSO may be still a better choice for women who have completed
their families; and a delayed hysterectomy and BSO for womenwho
have been treated with fertility-sparing therapy but subsequently
ﬁnish their families might be needed.
Secondary to the indolent nature of the LG-ESS and the effec-
tiveness of hormonal treatment, complete cytoreduction, even if
considered radical cytoreduction, is recommended in LG-ESS
[32e34]. In regard to surgical staging in patients with LG-ESS,
several studies have investigated the utility of lymph node dissec-
tion in these LG-ESS patients. The reported lymphatic involvement
of ESS ranged from 7% to 9% [16,35,36]. Although removal of
enlarged lymph nodes may be one of a completely cytoreductive
procedure, a survival beneﬁt has not been proven in the literature
[37]. Two studies evaluated 831 and 384 patients, respectively, and
found that lymphadenectomy did not provide the survival beneﬁts
for these patients with LG-ESS [16,35]. In addition, one Chinese
study showed that no beneﬁt was found for lymphadenectomy
regarding either recurrence-free survival or overall survival [32].Furthermore, one study further found that therewas no statistically
signiﬁcant differences of 5-year survival rate between node-
positive LG-ESS and node-negative LG-ESS (86% vs. 95%) [35]. All
maymake interpretation of the value of lymphadenectomy difﬁcult
in LG-ESS. Therefore, some suggested that distant resectionmust be
considered individually in the setting of metastatic diseases of
women with LG-ESS [38].
Recurrence
Although LG-ESS is an indolent tumor with a favorable prog-
nosis, recurrence rates might be higher, up to the range between
36% and 56% [36]. Recurrence occurs even in early-stage LG-ESS
with a median time to recurrence of 65 months [39]. The most
common sites for recurrence are abdomen and pelvis in 40e50% of
cases; however, 25% of current cases are found in the lung [40].
Because of relatively limited and focused areas of recurrence, it is
possible to consider the role of aggressive and intensive en-bloc
metastatectomy, similar to the treatment for other gynecological
malignancies [41,42]. For example, Thomas et al [34] reported that
two of three patients with recurrent LG-ESS had successfully
managed by complete surgical resection and postoperative adju-
vant therapy and these two patients had a long-term survival.
Other reports also showed four of six patients with recurrent LG-
ESS who underwent secondary cytoreduction had a mean follow-
up of 16-year survival [33]. However, the reported cases are too
rare; therefore, it is difﬁcult to ascertain the beneﬁt of such therapy
[38].
HG-ESS
One of the main highlights of the 2014 World Health Organi-
zation classiﬁcation of uterine mesenchymal tumors is the rein-
troduction of HG-ESS as a distinct entity, based on the identiﬁcation
of YWHAE-NUTM2A/B (YWHAE-FAM22A/B) gene (tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein,
epsilon isoform- family with sequence similarity 22) fusion
(Table 2), which gives rise to a 14-3-3 oncoprotein, as a recurrent
event in this moremalignant subgroup of tumors (Table 1), which is
intermediate between LG-ESS and UUS [2,4,43e47]. Unlike LG-ESS,
patients with HG-ESS have earlier and more frequent recurrences
(often <1 year) and are more likely to die of disease [46].
Pathology
Grossly, HG-ESS may be a polypoid intracavitary mass, or
intramural mass, poorly circumscribed with myometrial invasion
[1,2]. On sectioning of HG-ESS, the tumor is ﬂeshy with extensive
areas of hemorrhage and necrosis [1,2]. HG-ESS often contains both
morphologically low- and high-grade areas appreciable on low
power examination as hyper- and hypocellular areas (biphasic)
[2,4]. Microscopically, the tumor consists predominantly of high-
grade round, epithelioid cells with scant to moderate amounts of
eosinophilic cytoplasm, containing round to oval vesicular nuclei
(4e6 times the size of a lymphocyte) with irregular nuclear con-
tours and nucleoli. HG-ESS has an extensive permeative growth
ﬁnger-like or tongue-like myometrial and vascular invasion, and
forms nested and corded growth with delicate curvilinear vascu-
lature [2,4]. Mitotic activity is strikingly apparent and often greater
than 10 per 10 high-power ﬁelds. Necrosis is usually present.
Immunohistochemically, HG-ESS is typical negative CD10, ER,
and PR, but shows strong diffuse cyclin D1 immunoreactivity (>70%
nuclei) and typically c-kit positive immunoactivity but Discovered
On Gastrointestinal stromal tumors protein 1 (DOG1) negative
staining [1,4]. CD 117 is often positive in HG-ESS [2]. However, the
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cellular” areas in the HG-ESS; careful evaluation is critical. Nucci [2]
emphasized the following key points to hint the possibility of
diagnosed HG-ESS, including (1) in a tumor with marked mitotic
activity (>20e30 mitoses/10 high-power ﬁelds); (2) loss of hor-
mone receptors; (3) additional sampling to exclude the possibility
of HG-ESS for ﬁbrous or myxoid appearance; (4) negative for
smooth muscle markers; (5) diffusely positive for c-kit but negative
for DOG1; (6) diffusely positive for cyclin D1 but negative for
Epithelial Membrane Antigen (EMA) and/or broad spectrum cyto-
keratin (Table 1).
Treatment
Little is known about the natural course, prognostic factors and
optimal treatment of HG-ESS [47]. In addition, most reports
described the patients without further differentiating LG-ESS, HG-
ESS, and UUS. Furthermore, patients with HG-ESS typically present
with advanced stage diseases (FIGO IIeIV) and frequently have
recurrences, usually within a few years after initial surgery [1].
Median progression-free survival (PFS) and OS ranged from 7 to 11
months and 11 to 23 months, respectively [47]. Data from the
Surveillance, Epidemiology, and End Results database between
1988 and 2005 evaluated 464 patients with ESS who were treated
with at least a hysterectomy and information on tumor size, and
identiﬁed 96 patients with HG-ESS [48]. The results showed that
more than three-fourths of patients had a tumor size more than
5 cm (FIGO IB); two-thirds of patients had myometrial invasion;
and 18.7% of patients had cervical invasion (worst prognosis),
contributing to 51.4% and 43.5% of a 5-year OS rate for FIGO Stage IA
and FIGO Stage IB, respectively [48]. By contrast, for 368 patients
with LG-ESS, the prognosis is very good, with 5-year OS rates of
100% for FIGO IA and 93.5% for FIGO IB, respectively [48]. Finally,
due to the rarity of the disease, there are no prospective, random-
ized trials which have been completed yet. Therefore, the following
suggestions need further conﬁrmation.
The treatment of choice consists of hysterectomy and BSO. Un-
like LG-ESS, it is not clear whether the adnexa could be preserved in
premenopausal women with HG-ESS. Because stage is an impor-
tant prognostic factor, therefore, the metastases of pelvic and/or
para-aortic lymph nodes are associated with a poorer prognosis.
There is no indication that surgical removal will improve this
limited prognosis, because most recurrences occur in visceral sites
[49]. However, in the case of extensive disease, abdominal
debulking surgery, including extensive lymphadenectomy is rec-
ommended if feasible. The results of the Taiwan Gynecology
Oncology Group 2005 (TGOG-2005) showed the adequate
debulking surgery, including dissection of both pelvic and para-
aortic lymph nodes might provide a better rate of survival in
FIGO IIIeIV pure endometrioid-type endometrial cancer [42],
whichmight also be applicable to themanagement of patients with
an extensive HG-ESS. In fact, residual disease has a negative prog-
nostic impact, and metastatectomy should be considered as for
other sarcoma [50].
Adjuvant therapy with external pelvic irradiation
Due to the poor prognosis in patients with HG-ESS, post-
operative adjuvant therapy might provide a better chance for sur-
vival. One prospective randomized study conducted by the
European Organization for Research and Treatment of Cancer
(EORTC) Gynecological Cancer Group study (protocol 55874)
showed that adjuvant external pelvic radiation did not improve PFS
and OS among women with FIGO IeII stage HG-ESS [51]. However,
it is interesting that it is believed that external pelvic irradiationmay decrease loco-regional recurrence in the patients with HG-
ESS; therefore, to date, this approach has been widely used as
adjuvant treatment for these patients [50]. Our comment is that
external pelvic irradiation could be considered in those HG-ESS
patients without residual tumors, although the survival beneﬁts
are not conﬁrmed.
Adjuvant chemotherapy with and without external pelvic
irradiation
Because the recurrence pattern of patients with HG-ESS is often
distant and visceral, it is reasonable to use an adjuvant chemo-
therapy (CT) in the management of this particularly aggressive
disease. A study of the French Sarcoma Group (SARCGYN study)
enrolled 81 patients with FIGO Stage IeIII uterine sarcoma (nine
patients with HG-ESS), who were randomly allocated to adjuvant
CT (doxorubicin, ifosphamide and cisplatin) followed by external
pelvic irradiation or external pelvic irradiation alone [52]. The re-
sults showed that the addition of CT to radiotherapy increased the
3-year disease-free survival rate (55% vs. 41%, p¼ 0.048) [52]. There
was a trend toward an improvement in 3-year OS (81% vs. 69%),
although it did not reach statistical signiﬁcance [52]. Although the
data of the SARCGYN study seemed to favor the beneﬁts of CT and
the following external pelvic irradiation, based on the limited data
available to date, the beneﬁts of this approach deserves further
investigation.
Cytotoxic CT in the form of doxorubicin and ifosfamide or
gemcitabine plus docetaxel and doxorubicin has been noted to
show activity in HG-ESS [36,53e56]. The effect of treatment on
persistent and/or recurrent HG-ESS is poor, particularly for patients
who have the recurrence after the ﬁrst line CT. Furthermore, when
these patients received the second-line CT, reusing single agent or
multiagent CT, such as doxorubicin, ifosfamide, cisplatin, topotecan,
paclitaxel, docetaxel, gemcitabine, trabectedin and gemcitabine
combined with docetaxel), the effectiveness of these regimen is
only 5e27% [53,57e60]. A general treatment algorithm for ESS is
presented in Figure 1.
UUS
UUS is, a high-grade sarcoma, extremely rare, lacking a speciﬁc
line of differentiation, which is a diagnosis of exclusion (the
wastebasket category, which fails to fulﬁll the morphological and
immunohistochemical criteria of translocation-positive ESS) [2,4].
Patients with UUS often have postmenopausal bleeding or symp-
toms/signs secondary to extrauterine spread; therefore, more than
60% of patients are far-advanced stage diseases (FIGO Stage IIIeIV)
and associated with a very poor prognosis (<2-year survival) [1].
Grossly, UUS is a relatively large ﬂeshy tumor demonstrating
destructive inﬁltrative growth into the uterinewall, associatedwith
extensive necrosis and/or hemorrhage [4]. Microscopically, the
tumors show sheets or fascicles of highly atypical nondescript cells,
with a brisk mitotic activity. Lymphovascular invasion is common.
Table 1 shows the key factors used to diagnose UUS.
Despite limited evidence, recommended surgical treatment for
UUS is total hysterectomy and BSO. It is unclear whether lympha-
denectomy provides survival beneﬁts for UUS [55]. Due to complex
biological characteristics and unknown etiology, the value and
better choices of adjuvant therapy are still under investigation.
Therefore, there is no conclusive data available yet. The main risk is
hematogenous spread and distant metastases, suggesting that CT
might be an option. Similar to treatment of HG-ESS, doxorubicin
and/or ifosfamide are frequently used in clinical practice. The
available regimens include trabectedin, gemcitabine, and doce-
taxel. Of course, the other choices identical to the management of
Figure 1. A ﬂow chart for clinical practice in the management of women with a diagnosed uterine ESS. CT¼chemotherapy; ESS¼ endometrial stromal sarcoma; FIGO¼ Federation
International Gynecology and Obstetrics; RT¼ radiation therapy.
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women with UUS. Because there is no data supported by ran-
domized trials, the treatment for persistent and recurrent UUS can
be similar to soft tissue sarcomas at other sites.
Adenosarcoma
Adenosarcoma is a mixed tumor of benign glandular epithelium
and low-grade sarcoma, usually of endometrial stromal type [1].
The stage system of the adenosarcoma differs from that of uLMS
and ESS (Table 3) [3]. Grossly, adenosarcoma is a polypoid tumor,
typically ﬁlling and distending the uterine cavity. Sometimes, a
sarcomatous component might overgrow, resulting in a larger size
with a ﬂeshy, hemorrhagic and necrotic cut surface. Microscopi-
cally, the stroma typically concentrates around the glands forming
periglandular cuffs [1]. The prognosis of adenosarcoma is favorable,
although one-fourth of patients might ﬁnally die of their disease.
The golden standard therapy is total hysterectomy and BSO. It is not
clear whether BSO and/or lymphadenectomy should be included inTable 3
2014 FIGO and 010 American Joint Committee on Cancer system-TNM staging for ut
FIGO TNM Deﬁn
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IV
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FIGO¼ Federation International Gynecology and Obstetrics; TNM¼ tumor, lymph nthe management of women with adenosarcoma [49]. The role of
adjuvant therapy has not been established. In addition, for meta-
static and recurrent patients with adenosarcoma, the proposed
approach is also unavailable. The possible strategy might be indi-
vidualized, including complete resection for operable disease,
palliative radiotherapy for local nonresectable recurrence or post-
operative adjuvant therapy for isolated tumor after meta-
statectomy, CT containing ifosfamide or doxorubicin-based
combination for disseminated disease [49]. The management al-
gorithm is shown in Figure 1.
Future perspectives
The scope of the clinical problems of uterine sarcomas includes
raremalignancy, heterogeneous, complex biological characteristics,
unknown etiology, and unknown risk factors; therefore, a multi-
disciplinary approach might be essential for optimal care. There are
many ongoing clinical trials to evaluate the effectiveness of
different approaches in the management of advanced soft tissueerine adenosarcoma.
ition
or limited to uterus
or limited to endometrium/endocervix without myometrial invasion
than or equal to half myometrial invasion
than half myometrial invasion
or extends beyond the uterus but limited within the pelvic cavity
xal involvement
lvement of other pelvic tissues
or invades abdominal tissues (not just protruding into the abdominal cavity)
site
than one site
ic and/or para-aortic lymph node metastases
or invades bladder and/or rectum
nt metastasis
ode and metastases.
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conducted by European Organization for Research and Treatment
of Cancer (EORTC) (EORTC 62012) enrolled 455 patients at 38
hospitals in 10 countries (age 60 years) to compare doxorubicin
and intensiﬁed doxorubin plus ifosfamide for advanced soft tissue
sarcomas (locally advanced, unresectable, or metastatic high-grade
soft-tissue sarcoma) [61]. During the median follow-up of 56 and
59 months, median PFS was signiﬁcantly higher for the multiagent
group than for the doxorubicin group (7.4 months. 95% CI 6.6e8.3
months vs. 4.6 months, 95% CI 2.9e5.6 months, stratiﬁed log-rank
test p¼ 0.003) [61]. In addition, more patients in the multiagent
group than in the doxorubicin group had an overall response [60
(26%) of 227 patients vs. 31 (14%) of 228, p< 0.006] [61]. However,
there was no signiﬁcant difference in OS between the two groups
(median OS 14.3 months, 95% CI 12.5e16.5 months in the multi-
agent group vs. 12.8 months, 95% CI 10.5e14.3 months in the
doxorubicin group; hazard ratio 0.83, 95% CI 0.67e1.03), suggesting
that the use of intensiﬁed doxorubicin and ifosfamide for palliation
of advanced soft-tissue sarcoma might not provide a better chance
of survival [61].
In addition to conventional CT, target therapy might be another
choice in the management of these highly lethal diseases. Many
Phase III studies with pazopanib, regorafenib, muramyl tripeptide,
and ridaforolimus are still ongoing [62]. Other promising agents that
are still in earlier stages of development such as CDK4 and MDM2
inhibitors, cedirabnib, eribulin, and crizotinib, are also being tested
[62e65]. We hope that the results of these studies will provide a
better chance of survival in patientswith sarcoma in the near future.
Conclusion
Standard treatment for early- and far-advanced ESS is hysterec-
tomyplus BSOand complete cytoreductionof the tumor en blocwith
adherent structures, respectively, even if not overtly inﬁltrated.
Similar to the management for patients with uLMS [3], for early-
stage (uterus-limited) ESS diseases, an en bloc and intact resection
of tumor (no morcellation) might be of paramount importance
[66,67], even though the uteruswas removed byminimally invasive
surgery and the diagnosis of ESS was accidental. For far-advanced
ESS, adequate cytoreduction and metastatectomy might provide a
better chance for survival. Adjuvant radiotherapyandchemotherapy
are not administered routinely because the survival beneﬁts are
doubtful, especially for those patients with totally eradicated tu-
mors. Treatment outcomes in HG-ESS and UUS are still disap-
pointing, especially in patients with inoperable, locally advanced,
recurrent and/ormetastatic diseases.Available evidence showed the
following regimens could be tried, including the single agent of
doxorubicin, ifosfamide, trabectedin, and gemcitabine, and the
combination of therapy, such as doxorubicin plus ifosfamide.
Doxorubicin plus ifosfamide can be used for rapid palliation, stop-
ping rapidly progressing disease, or to facilitate patients to become
surgical candidates [68,69]. This is a concept of neoadjuvant therapy
for relatively bulky-sized tumors [70,71]. In addition to further in-
formation provided by randomized clinical trials, future efforts
could focus on better deﬁning themolecular etiology of ESS in order
to provide better care for patients with uterine sarcomas.
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